Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients

Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients

Bibliographic Details
Main Authors:	Carmona-Fernandes, Diana, Santos, Maria José, Perpétuo, Inês Pedro, Fonseca, João Eurico, Canhão, Helena
Format:	Online
Language:	English
Published:	BioMed Central 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308110/

Similar Items

Anti-ribosomal P protein IgG autoantibodies in patients with systemic lupus erythematosus: diagnostic performance and clinical profile
by: Carmona-Fernandes, Diana, et al.
Published: (2013)

Salivary soluble receptor activator of nuclear factor kappa B ligand/osteoprotegerin ratio in periodontal disease and health
by: Tabari, Zahra Alizadeh, et al.
Published: (2013)

Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor-κB Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus
by: Lambrinoudaki, Irene, et al.
Published: (2013)

Effect of Breastfeeding on Serum Osteoprotegerin and Soluble Receptor Activator of Nuclear Factor-Kappa B Ligand in Full Term Neonates
by: Rafeey, Mandana, et al.
Published: (2013)

Early Vascular Alterations in SLE and RA Patients—A Step towards Understanding the Associated Cardiovascular Risk
by: Santos, Maria José, et al.
Published: (2012)

Effect of gallium nitrate on the expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand in osteoblasts in vivo and in vitro
by: LI, JINGWU, et al.
Published: (2016)

Response measures influence comparative effectiveness of biological drugs in rheumatoid arthritis
by: Canhao, Helena, et al.
Published: (2012)

Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?
by: Romão, Vasco Crispim, et al.
Published: (2013)

Cutaneous Manifestations of Systemic Lupus Erythematosus
by: Uva, Luís, et al.
Published: (2012)

The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts
by: Burgess, Teresa L., et al.
Published: (1999)

Increased concentration of serum soluble LAG3 in systemic lupus erythematosus
by: Yu, Seri, et al.
Published: (2012)

Elevated levels of soluble intercellular adhesion molecule -1 in systemic lupus erythematosus
by: Kljukvina, N, et al.
Published: (2001)

Decreased serum level of soluble-leptin-receptor in patients with systemic lupus erythematosus
by: Bagheri, K, et al.
Published: (2012)

Association of FAS and FAS Ligand Genes Polymorphism and Risk of Systemic Lupus Erythematosus
by: Moudi, Bita, et al.
Published: (2013)

Expression of osteoprotegerin and osteoprotegerin ligand in giant cell tumor of bone and its clinical significance
by: YU, XIUCHUN, et al.
Published: (2013)

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
by: Widschwendter, Martin, et al.
Published: (2015)

Isoliquiritigenin Inhibits Metastatic Breast Cancer Cell-induced Receptor Activator of Nuclear Factor Kappa-B Ligand/Osteoprotegerin Ratio in Human Osteoblastic Cells
by: Lee, Sun Kyoung, et al.
Published: (2015)

Soluble TRAIL does not impair the anti-osteoclastic activity of osteoprotegerin
by: Zauli, Giorgio, et al.
Published: (2008)

Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis
by: Giaginis, Constantinos, et al.
Published: (2012)

Role of Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand in Bone Loss Related to Advanced Chronic Obstructive Pulmonary Disease
by: Ugay, Ludmila, et al.
Published: (2016)

Mycobacterium tuberculosis 10-kDa co-chaperonin regulates the expression levels of receptor activator of nuclear factor-κB ligand and osteoprotegerin in human osteoblasts
by: ZHANG, YUANYU, et al.
Published: (2015)

Drugs for discoid lupus erythematosus
by: Jessop, Sue, et al.
Published: (2017)

Neuropsychiatric Systemic Lupus Erythematosus
by: Popescu, Alexandra, et al.
Published: (2011)

Complement and systemic lupus erythematosus
by: Walport, Mark J
Published: (2002)

Systemic lupus erythematosus
by: Manson, Jessica J, et al.
Published: (2006)

CONGENITAL LUPUS ERYTHEMATOSUS
by: Bhatt, Taseer Ahmed, et al.
Published: (2011)

Cytokines in Systemic Lupus Erythematosus
by: Poole, Brian D., et al.
Published: (2010)

Neonatal Lupus Erythematosus
by: Lun Hon, Kam, et al.
Published: (2012)

Bullous Systemic Lupus Erythematosus
by: Grover, Chander, et al.
Published: (2013)

Systemic Lupus Erythematosus
by: Okamoto, Hiroshi, et al.
Published: (2012)

Systemic Lupus Erythematosus
by: Putterman, Chaim, et al.
Published: (2012)

Systemic Lupus Erythematosus 2014
by: Anaya, Juan-Manuel, et al.
Published: (2014)

Cutaneous lupus erythematosus: An update
by: Grönhagen, Carina M, et al.
Published: (2014)

Moulage: “Lupus erythematosus”
by: Patzak, Beatrix
Published: (2011)

Systemic lupus erythematosus and thrombosis
by: Bazzan, Mario, et al.
Published: (2015)

Pathophysiology of cutaneous lupus erythematosus
by: Achtman, Jordan C, et al.
Published: (2015)

Lupus Erythematosus and Collagen Diseases
by: Singh, Amarjit
Published: (1955)

Disseminated Lupus Erythematosus
by: Konar, N. R., et al.
Published: (1950)

Belimumab in Systemic Lupus Erythematosus
by: Srivastava, Ankita
Published: (2016)

Dermoscopy of discoid lupus erythematosus
by: Jha, Abhijeet K, et al.
Published: (2016)